#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# FORM 12b-25 NOTIFICATION OF LATE FILING

SEC FILE NUMBER

heck one): 🖌 Form 10-K 🔄 Form 20-F 🔄 Form 11-K 🔄 Form 10-Q 🔄 Form 10-D 🔄 Form N-SAR 🔄 Form N-CS	R
For Period Ended: 9/30/2009	
Transition Report on Form 10-K	
Transition Report on Form 20-F	
Transition Report on Form 11-K	
Transition Report on Form 10-Q	
Transition Report on Form N-SAR	
For the Transition Period Ended:	
Read Instructions (on back page) Before Preparing Form. Please Print or Type.	]
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.	

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

# PART I - REGISTRANT INFORMATION

# Ohr Pharmaceutical, Inc

Full Name of Registrant

# **BBM Holdings, Inc**

Former Name if Applicable

#### 1245 Brickyard Rd, # 590


Address of Principal Executive Office (Street and Number)

#### Salt Lake City, Utah 84106

City, State and Zip Code

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;



(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

#### PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)

The Registrant's Annual Report on Form 10-K could not be filed within the prescribed time period because of delays in the preparation of the Registrant's financial statements. The Registrant is a small company with limited resources available to dedicate to the preparation of this report, despite having engaged an outside consultant to assist in the process. These developments put a tremendous strain on being able to file in the allotted time frame.

# PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

	Andrew Limpert	347	753-4389	
	(Name)	(Area Code)	(Telephone Number)	
(2)	Have all other periodic reports required under Section 13 or 15(d) o Investment Company Act of 1940 during the preceding 12 months o such report(s) been filed? If answer is no, identify report(s).			
(3)	Is it anticipated that any significant change in results of operations f reflected by the earnings statements to be included in the subject rep		the last fiscal year will be Yes No 🗸	
	If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.			
	Ohr Pharamceut	ical, Inc		
	(Name of Registrant as Sp	ecified in Charter)		
has	caused this notification to be signed on its behalf by the undersigned	hereunto duly authorized.		

Date: December 29, 2009

By: /s/ Andrew Limpert